IntroductionThis post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D).Research design and methodsThe Semaglutide Real-world Evidence (SURE) studies had a duration of ~30 weeks. Changes in glycated hemoglobin (HbA_1c) and body weight (BW) were analyzed for the overall population and the following baseline subgroups: GLP-1RA-naïve/GLP-1RA switchers; body mass index <25/≥25–<30/≥30–<35/≥35 kg/m²; age <65/≥65 years; HbA_1c <7%/≥7–≤8%/>8–≤9%/>9%; T2D duration <5/≥5–<10/≥10 years. Data for patients achieving treatment targets were analyzed in the overall population and the baseline HbA_1c ≥7% subgroup.ResultsOf 1212 patients, 960 were GLP-1RA-naïve and 252 had switched to semaglutide from another GLP-1RA. In the overall population, HbA_1c was reduced from baseline to end of study (EOS) by –1.1% point and BW by –4.7 kg; changes were significant for all subgroups. There were significantly larger reductions of HbA_1c and BW in GLP-1RA-naïve versus GLP-1RA switchers and larger reductions in HbA_1c for patients with higher versus lower baseline HbA_1c. At EOS, 52.6% of patients in the overall population achieved HbA_1c <7%. No new safety concerns were identified in any of the completed SURE studies.ConclusionsIn this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA_1c and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice.Trail registration numbersNCT03457012; NCT03631186; NCT03648281; NCT03876015.